EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma

Aysel Bayram, Sidar Bagbudar, Hasan Karanlık, Neslihan Cabıoglu, Adnan Aydıner, Semen Onder, Ekrem Yavuz

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07601-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Aysel Bayram und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, 34390, Faith, Istanbul, Turkey. aysel.bayram@istanbul.edu.tr. Hauptthemen laut MEDLINE: Breast Neoplasms, Stromal Cells, Receptors, Estrogen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to determine estrogen receptor (ER) expression in stromal cells in postchemotherapy tumor bed (PCTB) and its relationship with tumor regression and tumor characteristics.

Methods

The study included 490 breast cancer patients who received neoadjuvant chemotherapy (NAC). We performed ER in stromal cells in all resection specimens and available pre-treatment core biopsy materials of 299 patients immunohistochemically.

Results

Two hundred and forty-two (49.4%) cases were negative for ER in the stromal cells of the PCTB, and 248 (50.6%) cases were positive. ER-positive stromal cells in the PCTB correlated with a higher regression rate (90.2 vs 68.6%) and lower mean residual cancer burden value (1.366 vs 2.424) compared to ER-negative cases ( p < 0.001). Stromal ER positivity was more prevalent in cases achieving pathologic complete response (pCR) (68.1%) compared to those without pCR (39.8%, p < 0.001). ER positivity in stromal cells was more common in non-luminal tumors than in luminal ones. Multivariate analysis identified stromal ER positivity (OR: 3.059, 95% CI [1.947–4.807], p < 0.001), intrinsic subtype (Odds ratio (OR): 1.477, 95% confidence interval (CI) [1.102–1.980], p = 0.009), and Ki67 index (OR: 1.028, 95% CI [1.104–1.041], p < 0.001) as independent predictors of pCR. In core biopsies before NAC, 270 cases (90.3%) and 29 cases (9.7%) were negative and positive in stromal cells, respectively. Out of the cases with ER-negativity in stromal cells before NAC, 132 (48.9%) converted to ER positivity in stromal cells of PCTB and displayed a high regression rate (89.8%).

Conclusion

This is the first study regarding ER expression in the stroma of breast carcinoma that compares treatment response after NAC. We showed that the increase in ER positivity in the stromal cells of the PCTB is correlative with the complete response and tumor subtypes. In this manner, ER positivity in stromal cells will soon serve as a cornerstone for individualized treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsStromal CellsReceptors, EstrogenHumansFemaleNeoadjuvant TherapyMiddle AgedAdultAgedTreatment OutcomeBiomarkers, TumorPrognosisImmunohistochemistryAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, Adjuvant

Stichwörter der Autor:innen

Breast carcinomaEstrogen receptorNeoadjuvant chemotherapyStromal cellTumor bed

Substanzen

Receptors, EstrogenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, 34390, Faith, Istanbul, Turkey. aysel.bayram@istanbul.edu.tr.
  • Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, 34390, Faith, Istanbul, Turkey.
  • Department of Surgical Oncology Unit, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.

Förderung

  • Istanbul University

Zitieren

APA

Bayram, A., Bagbudar, S., Karanlık, H., Cabıoglu, N., Aydıner, A., Onder, S., & Yavuz, E. (2025). Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07601-6

Vancouver

Bayram A, Bagbudar S, Karanlık H, Cabıoglu N, Aydıner A, Onder S, et al. Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07601-6

BibTeX
@article{Bayram2025,
  author = {Bayram, Aysel and Bagbudar, Sidar and Karanlık, Hasan and Cabıoglu, Neslihan and Aydıner, Adnan and Onder, Semen and Yavuz, Ekrem},
  title = {Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07601-6}
}
Kostenlos starten →